Skip to content
★ Sign in to follow
대웅

대웅 Stock: price and insider trades · South Korea

KR·Mcap ₩676.8BHealth Care

No insider purchase over the last 90 days. The latest, by 송기호, was filed 02 May 2024.

대웅: what insiders have been doing

This page follows insider dealings at 대웅 as filed with DART (FSS), a company from the Health Care sector. Between 8 November 2025 and 8 November 2026, 1 insider published 1 filing.

The filings describe grants, exercises and other transfers rather than trades on the open market. Compensation-driven entries like these are tracked, but they say little about how insiders judge the share price.

Over the last twelve months, not one insider purchase of 대웅 stock was filed.

Across the 2,657 companies tracked on its exchange, the median is 7 filings; at 1 filing, this issuer sits below that mark. Over the whole record (from 2021), the tally stands at 9 purchases and 1 sale.

Elsewhere in the same sector, our signals recently picked up insider purchases at Dynavox Group AB and Vetoquinol SA. This summary is built from DART (FSS) disclosures alone and does not predict where the share price will go.

Insider Decl.
16
Thresholds
n/a
Buy Volume
€68M
9 ops. · all time
Sell Volume
€8M
1 ops. · all time

Who traded when

BuySale
국민연금공단1 sale

Since the insiders bought

  • Filed 02 May 2024 · 922 days ago · €34k
    +2.6%
    Entry ₩18,770 · Close at T+365 ₩19,260
  • Filed 02 May 2024 · 922 days ago · €68k
    +2.6%
    Entry ₩18,770 · Close at T+365 ₩19,260

Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.

This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.

Fundamental score
Ranked 6,231 of 26,911 companies
65.2
score / 100
Value
67
Quality
63
FCF yld-13%
Earn yld26%
EV/EBITDA4.9x
ROE13%
Gross mgn53%
Net mgn8.5%
Debt/EBITDA2.7x
Pillars2/3

Transparent value + quality ranking, distinct from the insider signal.

Financial data

as of FY 2025

FY ended December 2025 · cache

₩16,100
Analyst consensus
·
Income statement
Revenue₩2.1T
Gross profit₩1.1T53% margin
EBITDA₩320.4B15% margin
Net income₩175.1B8.5% margin
Valuation
Beta0.26
Balance sheet & cash
Market cap₩676.8B
Total debt₩878.2B
Free Cash Flow-₩90.4B
Debt / Equity52%
Profitability & ownership
ROE12.9%
ROA4.7%
% insiders38.3%
% institutions8.4%
Last declaration on 26 February 2026
Declarations16 total
  • ●
    Executives
    Executives(filed)
    0DART
  • ▼
    대량보유자Executives
    €8.2Mest.0DART
    596,278 sharesKRXDART:20251001000324
  • ▲
    Executives
    50M KRW22DART
    2,745 shares@ ₩18,196.00100.0% of flowShareKRXDART:20240502000579
    Canonical exit: 25 Jul 2024 (T+90)
  • ▲
    Executives
    100M KRW22DART
    5,491 shares@ ₩18,196.00100.0% of flowShareKRXDART:20240502000566
    Canonical exit: 25 Jul 2024 (T+90)
  • ▲
    Executives
    €54kest.0DART
    5,241 sharesKRXDART:20230704000160
    Canonical exit: 8 Aug 2023 (T+90)
  • ●
    Executives
    Executives(filed)
    0DART
  • ●
    Executives
    Executives(filed)
    0DART
  • ▲
    기타비상무이사Executives(filed)
    0DART
    ShareKRXDART:20230314000635
    Canonical exit: 12 Jun 2023 (T+90)
  • ▲
    Executives(filed)
    €67.8Mest.0DART
    2,907,771 sharesKRXDART:20220405001345
    Canonical exit: 4 Jul 2022 (T+90)
  • ●
    Executives
    Executives(filed)
    0DART
  • ●
    Executives
    Executives(filed)
    0DART
  • ▲
    기타비상무이사Executives(filed)
    0DART
    ShareKRXDART:20210430001508
    Canonical exit: 29 Jul 2021 (T+90)
  • ▲
    기타비상무이사Executives(filed)
    0DART
    ShareKRXDART:20210430001480
    Canonical exit: 29 Jul 2021 (T+90)
  • ▲
    Executives(filed)
    €142kest.0DART
    5,241 sharesKRXDART:20210430001468
    Canonical exit: 29 Jul 2021 (T+90)
  • ●
    Executives
    Executives(filed)
    0DART
  • ▲
    기타비상무이사Executives(filed)
    0DART
    ShareKRXDART:20210222002181
    Canonical exit: 23 May 2021 (T+90)

16 of 16 declarations

About 대웅

Daewoong is a South Korean company specializing in the healthcare and pharmaceutical sector. It is listed on the XKRX market.

Recent ranked signals in the same sector

Purchases our model currently ranks for the recommendations list.

All recommendations